Supplementary Data for Reseach Brief:

Overcoming PD-1 Blockade Resistance With CpG-A Toll-Like Receptor 9 Agonist


Vidutolimod in Patients With Metastatic Melanoma

Prior therapies received for the patient shown in Fig. 1E


- Ipilimumab (adjuvant setting)
- Interferon-α (adjuvant setting)
- Pembrolizumab (best response of stable disease; last response of progressive disease)
- Aflibercept (best response of stable disease)
- Interleukin-2 (best response of stable disease)

Prior therapies received for the patient shown in Fig. 1F


- Interferon-α (best response of progressive disease)
- Ipilimumab (best response of progressive disease)
- Dabrafenib and trametinib (best response of partial response; last response of progressive disease)
- Pembrolizumab (best response of progressive disease)
- Dabrafenib and trametinib as a temporising measure immediately prior to study entry (response unknown)



Supplementary Figure 1. Study flow diagram. Patient enrollment into each vidutolimod dose level, schedule of vidutolimod administration, and patient disposition at data cutoff are shown. The 1-mg vidutolimod dose level was evaluated with schedule A only; all other doses were evaluated with both dosing schedules. ^aTwo patients (one in the 7.5-mg cohort and one in the 10-mg cohort) discontinued treatment based on investigator decision due to a lack of injectable tumor lesions, which was confirmed by negative biopsy.




Supplementary Figure 2. Incidence of TRAEs with vidutolimod plus pembrolizumab treatment by vidutolimod injection number. Incidence of TRAEs during each injection cycle from the start of vidutolimod plus pembrolizumab therapy. Patients were counted only once for the highestgrade event within each injection cycle. All AEs shown were treatment emergent. CTCAE, Common Terminology Criteria for Adverse Events; Q1W, every week; Q3W, every 3 weeks.







from baseline)	Baseline	Week 11	Week 23	Week 35	Week 48	Week 59	Week 72	Week 84	Week 96	Week 108	Week 120	Week 132	Week 144	
T01	29.7	22.5	19.1	15.0	13.5	10.6	10.5	6.7	7.1 (–75.9%)	6.5	6.8	6.9	5.9	
Nontarget lesions		(-24.1%)	(-35.6%)	(-49.3%)	(-54.6%)	(-64.3%)	(-64.4%)	(-77.3%)	(-/5.9%)	(-78.0%)	(-77.2%)	(-76.8%)	(-80.2%)	
NTL01	Present	Progression	Progression	Progression	Stable	Stable	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	
NTL02	Present	Progression	Progression	Stable	Stable	Stable	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	
NTL03	Present	Progression	Progression	Stable	Stable	Stable	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	
NTL04	Present	NE	NE	NE	NE	NE	NE	Stable	Stable	Stable	Stable	Stable	Stable	
New lesion														
NL01		Present	Stable	Stable	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	Resolved	
Time response assessments														
RECIST	Undefined	PD	PD	PD	PR	PR	PR	PR	PR	PR	PR	PR	PR	
iRECIST	Undefined	iUPD	iUPD	iUPD	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR	



Supplementary Figure 3. RECIST response in two patients with initial PD per RECIST v1.1. (A) The percent change in target lesion diameter and the status of nontarget lesions and new lesions over time in a patient with PR by iRECIST as assessed by blinded central review. This patient previously received granulocyte macrophage colony-stimulating factor (adjuvant setting), ipilimumab (adjuvant setting), and pembrolizumab (best response of CR), and this patient had PD as last response when vidutolimod plus pembrolizumab therapy began. (B) The percent change in the sum of target lesion diameters and the status of non-target lesions and new lesions over time in another patient with PR by iRECIST as assessed by blinded central review. This patient previously received ipilimumab (best response of PR), melphalan/dactinomycin (best response of PD), biochemotherapy (best response of PD), temozolomide (best response of PD), pembrolizumab (best response of PD), MLN-2480 (best response of PD), SD-101 (a CpG-C oligodeoxynucleotide) plus pembrolizumab (best response of PD), and entinostat plus pembrolizumab (best response of PD). a The target lesion used in central review was not included in field of view and therefore was not evaluable at week 42 and week 54 of follow-up. ^bNew brain lesion underwent surgical resection. At week 12, the patient developed an acute central nervous system bleed and was found to have a metastasis. Since no baseline or prescreening head imaging had been performed, this lesion was designated as new, per RECIST v1.1, and was deemed as PD. Upon resection, the pathology showed significant necrosis and hemorrhage. No new central nervous system lesions appeared during subsequent therapy. iPR, PR by iRECIST; iRECIST, modified RECIST v1.1 for immune-based therapeutics; iUPD, unconfirmed PD by iRECIST; NE, not evaluable; NL, new lesion; NTL, nontarget lesion.




Supplementary Figure 4. Change in injected and noninjected target lesions. Percent change from baseline in the SLD of injected and noninjected target lesions for all dose-escalation patients with non-injected target lesions (n = 30).



Supplementary Figure 5. Cytokine induction. **(A)** Mean (\pm SD) concentration of IFN- α , **(B)** IL-6, and **(C)** IL-10 within PBMC supernatant after treatment with a CpG-A positive control (2216), G10 (naked CpG-A from vidutolimod), vidutolimod (G10+VLP) + anti-Q β , vidutolimod alone, anti-Q β alone, a CpG-B positive control (2006), a CpG-C agonist (SD-101), a TLR4 agonist (MPL), and a TLR7/8 agonist (R-848) in vitro. All samples were run in duplicate. The experiment

shown was one of three performed with similar results. * Values out of range (below the limit of quantitation).



Supplementary Figure 6. Immune response to vidutolimod. **(A)** The kinetics of anti-Q β antibody induction by vidutolimod dose cohort are shown. No association between anti-Q β antibody concentration and vidutolimod dose level was observed. **(B)** The lack of association of anti-Q β antibody concentration with clinical response is depicted. Patients with unknown best

RECIST v1.1 response did not have a postbaseline scan. Analysis for both panels includes patients with available anti-Q β data (*n* = 35). IgG, immunoglobulin G.

Supplementary Table 1. Baseline disease sites and objective response rate by site of baseline

disease

		ORR by site of
	No. of patients,	baseline disease,
Baseline disease sites	N (% of N=44)	% (n/N)
Skin only	3 (7)	67 (2/3)
Lymph nodes ± skin	6 (14)	33 (2/6)
Soft tissue ± skin and lymph nodes	7 (16)	29 (2/7)
Bone metastases without visceral metastases	2 (5)	0 (0/2)
Any visceral metastases	26 (59)	19 (5/26)
Lung metastases without other visceral metastases	8 (18)	25 (2/8)
Other visceral metastases ± lung metastases	17 (39)	18 (3/17)
Any liver metastases ± other visceral metastases	10 (23)	20 (2/10)
Any brain metastases ± other visceral metastases	1 (2)	0 (0/1)

Supplementary Table 2. Overall safety summary^a

	1-mg	3-mg	5-mg	7.5-mg	10-mg	All
	Cohort	Cohort	Cohort	Cohort	Cohort	Patients
	(<i>n</i> = 3)	(<i>n</i> = 16)	(<i>n</i> = 9)	(<i>n</i> = 6)	(<i>n</i> = 10)	(<i>N</i> = 44)
Patients with at least one						
Any-grade AE, n (%)	3 (100)	16 (100)	9 (100)	6 (100)	10 (100)	44 (100)
Treatment-related	3 (100)	15 (94)	9 (100)	6 (100)	10 (100)	43 (98)
Grade 3/4 AE, ^b n (%)	1 (33)	11 (69)	6 (67)	3 (50)	6 (60)	27 (61)
Treatment-related	1 (33)	8 (50)	4 (44)	2 (33)	5 (50)	20 (45)
Grade 5 AE, ^c n (%)	0	0	1 (11)	0	0	1 (2)
Treatment-related	0	0	0	0	0	0
Serious AE, n (%)	2 (67)	9 (56)	4 (44)	1 (17)	4 (40)	20 (45)
Treatment-related	0	5 (31)	3 (33)	1 (17)	3 (30)	12 (27)
AE leading to treatment discontinuation, ^d n (%)	0	1 (6)	2 (22)	0	1 (10)	4 (9)

^aAll AEs shown were treatment emergent.

^bAEs were manageable and transient.

^cOne pateint had a fatal AE (respiratory failure) that was assessed as unrelated to treatment.

^dTwo patients discontinued treatment because of TRAEs and two because of AEs related to disease progression.

Supplementary Table 3. Most common TRAEs^a

	Vidutolimod												
	1-mg Cohort		3-mg Cohort		5-mg Cohort 7.		7.5-mg	7.5-mg Cohort		10-mg Cohort		All Patients	
	(n=	=3)	(n=16)		(n=9)		(n=6)		(n=10)		(N=44)		
	Any	Grade	Any	Grade	Any	Grade	Any	Grade	Any	Grade	Any	Grade	
Incidence, n (%)	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	
Patients with ≥1	0 (400)	4 (00)	45 (04)	0 (50)	0 (400)		0 (400)	0 (00)	40 (400)	E (EQ)	40.(00)	00 (45)	
TRAE ^b	3 (100)	1 (33)	15 (94)	8 (50)	9 (100)	4 (44)	6 (100)	2 (33)	10 (100)	5 (50)	43 (98)	20 (45)	
TRAEs with ≥10% inc	idence in	all patier	nts										
Chills	2 (67)	0	11 (69)	1 (6)	6 (67)	0	5 (83)	1 (17)	10 (100)	0	34 (77)	2 (5)	
Fever	2 (67)	0	12 (75)	1 (6)	7 (78)	1 (11)	1 (17)	0	7 (70)	0	29 (66)	2 (5)	
Nausea	0	0	7 (44)	0	7 (78)	0	3 (50)	0	9 (90)	0	26 (59)	0	
Fatigue	1 (33)	0	7 (44)	1 (6)	4 (44)	0	4 (67)	0	5 (50)	0	21 (48)	1 (2)	
Vomiting	2 (67)	0	6 (38)	0	5 (56)	0	1 (17)	0	5 (50)	0	19 (43)	0	
Headache	0	0	7 (44)	0	4 (44)	0	1 (17)	0	5 (50)	0	17 (39)	0	
Hypotension ^b	0	0	7 (44)	3 (19)	4 (44)	2 (22)	2 (33)	1 (17)	4 (40)	1 (10)	17 (39)	7 (16)	
Injection-site pain	0	0	5 (31)	0	3 (33)	0	3 (50)	0	4 (40)	0	15 (34)	0	

	Vidutolimod											
	1-mg (Cohort	3-mg (Cohort	5-mg (Cohort	7.5-mg	Cohort	10-mg	Cohort	All Pa	tients
	(n=3)		(n=16)		(n=9)		(n=6)		(n=10)		(N=44)	
	Any	Grade	Any	Grade	Any	Grade	Any	Grade	Any	Grade	Any	Grade
Incidence, n (%)	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4
Diarrhea	1 (33)	0	3 (19)	0	3 (33)	0	3 (50)	0	3 (30)	0	13 (30)	0
Arthralgia	1 (33)	0	3 (19)	1 (6)	4 (44)	0	2 (33)	0	1 (10)	1 (10)	11 (25)	2 (5)
Decreased appetite	0	0	2 (13)	0	2 (22)	0	3 (50)	0	3 (30)	0	10 (23)	0
Dizziness	0	0	1 (6)	0	1 (11)	0	3 (50)	0	3 (30)	0	8 (18)	0
Rash	0	0	2 (13)	0	2 (22)	0	1 (17)	0	3 (30)	0	8 (18)	0
Constipation	1 (33)	0	2 (13)	0	1 (11)	0	2 (33)	0	1 (10)	0	7 (16)	0
Cough	1 (33)	0	1 (6)	0	3 (33)	0	0	0	1 (10)	0	6 (14)	0
Dyspnea	0	0	0	0	0	0	0	0	6 (60)	0	6 (14)	0
Injection-site erythema	0	0	1 (6)	0	2 (22)	0	2 (33)	0	1 (10)	0	6 (14)	0
Pruritus	0	0	1 (6)	1 (6)	2 (22)	0	2 (33)	0	1 (10)	0	6 (14)	1 (2)
Anemia	0	0	3 (19)	2 (13)	1 (11)	0	0	0	1 (10)	0	5 (11)	2 (5)

		Vidutolimod										
	1-mg Cohort		3-mg Cohort		5-mg Cohort		7.5-mg Cohort		10-mg Cohort		All Patients	
	(n=3)		(n=16)		(n=9)		(n=6)		(n=10)		(N=44)	
	Any	Grade	Any	Grade	Any	Grade	Any	Grade	Any	Grade	Any	Grade
Incidence, n (%)	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4	Grade	3/4
Flushing	0	0	2 (13)	0	2 (22)	0	0	0	1 (10)	0	5 (11)	0

^aAll AEs shown were treatment emergent.

^bNo treatment-related grade 5 AEs (deaths) occurred.

^cIn response to unexpected grade ≥3 hypotension events in the 3-mg vidutolimod dose cohort, the cohort was expanded to 16 patients

and a second dosing schedule was added.

Supplementary Table 4. Clinical response by on-study steroid use

	All Patients							
	(N=44)							
	Patients With CR or PR,	ORR by RECIST v1.1,						
On-Study Steroid Use ^a	n/N	% (95% CI)						
No steroids	5/24	21 (7–42)						
≥1 administration of <10 mg prednisone equivalent per day	1/4	25 (1–81)						
≥1 administration of >10 mg prednisone equivalent per day	5/16	31 (11–59)						
≥1 administration of >10 mg and <30 mg prednisone equivalent per day	1/3	33 (1–91)						
≥1 administration of >30 mg prednisone equivalent per day	4/13	31 (9–62)						

CI, confidence interval.

^aPatients counted once at their highest level of steroid use.